Share-based Payment Arrangement, Noncash Expense of DNA X, Inc. from 31 Mar 2018 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of noncash expense for share-based payment arrangement.
Summary
DNA X, Inc. quarterly and annual Share-based Payment Arrangement, Noncash Expense in USD history and change rate from 31 Mar 2018 to 31 Dec 2025.
  • DNA X, Inc. Share-based Payment Arrangement, Noncash Expense for the quarter ending 31 Dec 2025 was $159,000, a 55% decline year-over-year.
  • DNA X, Inc. Share-based Payment Arrangement, Noncash Expense for the twelve months ending 31 Dec 2025 was $1,541,000, a 1% increase year-over-year.
  • DNA X, Inc. annual Share-based Payment Arrangement, Noncash Expense for 2025 was $1,541,000, a 1% increase from 2024.
  • DNA X, Inc. annual Share-based Payment Arrangement, Noncash Expense for 2024 was $1,525,000, a 1.9% increase from 2023.
  • DNA X, Inc. annual Share-based Payment Arrangement, Noncash Expense for 2023 was $1,496,000, a 3.5% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Noncash Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Noncash Expense, Quarterly (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Noncash Expense, Annual (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Annual Change (%)

DNA X, Inc. Quarterly Share-based Payment Arrangement, Noncash Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,541,000 $159,000 -$197,000 -55% 01 Oct 2025 31 Dec 2025 10-K 15 Apr 2026 2025 FY
Q3 2025 $1,738,000 $166,000 -$207,000 -55% 01 Jul 2025 30 Sep 2025 10-Q 31 Oct 2025 2025 Q3
Q2 2025 $1,945,000 $926,000 +$454,000 +96% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $1,491,000 $290,000 -$34,000 -10% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $1,525,000 $356,000 -$102,000 -22% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2026 2025 FY
Q3 2024 $1,627,000 $373,000 +$2,000 +0.54% 01 Jul 2024 30 Sep 2024 10-Q 31 Oct 2025 2025 Q3
Q2 2024 $1,625,000 $472,000 +$114,000 +32% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $1,511,000 $324,000 +$15,000 +4.9% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $1,496,000 $458,000 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $371,000 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $358,000 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $309,000 +$26,000 +9.2% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q1 2022 $283,000 -$13,000 -4.4% 01 Jan 2022 31 Mar 2022 10-Q 08 May 2023 2023 Q1
Q1 2021 $296,000 +$73,000 +33% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $223,000 +$176,000 +374% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q1 2019 $47,000 +$14,000 +42% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q1 2018 $33,000 01 Jan 2018 31 Mar 2018 10-Q 24 Jun 2019 2019 Q1

DNA X, Inc. Annual Share-based Payment Arrangement, Noncash Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $1,541,000 +$16,000 +1% 01 Jan 2025 31 Dec 2025 10-K 15 Apr 2026 2025 FY
2024 $1,525,000 +$29,000 +1.9% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2026 2025 FY
2023 $1,496,000 -$55,000 -3.5% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $1,551,000 +$466,000 +43% 01 Jan 2022 31 Dec 2022 10-K 27 Mar 2024 2023 FY
2021 $1,085,000 -$2,000 -0.18% 01 Jan 2021 31 Dec 2021 10-K 20 Mar 2023 2022 FY
2020 $1,087,000 -$5,221,000 -83% 01 Jan 2020 31 Dec 2020 10-K/A 29 Jun 2022 2021 FY
2019 $6,308,000 +$6,056,000 +2403% 01 Jan 2019 31 Dec 2019 10-K 18 Mar 2021 2020 FY
2018 $252,000 01 Jan 2018 31 Dec 2018 10-K 27 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.